Achieve Life Sciences, Inc. ACHV 深 沪
等待开盘 02-07 09:30:00 美东时间
4.235
+0.285
+7.22%
华盛通- 最 高6.025
- 今 开4.10
- 成交量 52.26万股
- 最 低 3.91
- 昨 收 3.95
- 总市值 4100.28万
- 52周最高 6.025
- 市盈率 静 --
- 换手率 5.40%
- 52周最低 0.00
- 委 比 21.88%
- 总股本 968.19万
- 历史最高 6.025
- 量 比 0.83
- 振 幅 53.54%
- 历史最低 0.00
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking
Cytisinicline likely the best therapy to quit smoking, could be first FDA-approved cessation drug in 20 years.
2025-12-31 02:23
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Achieve生命科学任命临时首席医疗官
Achieve生命科学公司（ACHV）早盘下跌4.6%。该公司任命医学博士马克·鲁宾斯坦（Mark Rubinstein， M.D．）担任临时首席医疗官，接替辛迪·雅各布斯博士（医学博士）的职位。 鲁宾斯坦将专注于推进该公司用于治疗尼古丁依赖的金雀花碱研发项目。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-12 23:46
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
Achieve Life Sciences to present at Jefferies Global Healthcare Conference on June 4, 2025. CEO Rick Stewart will discuss cytisinicline, a plant-based alkaloid for smoking cessation, which has received FDA Breakthrough Therapy designation. The company plans to submit its new drug application in June 2025 after completing Phase 3 studies.
2025-05-28 12:30
Achieve Life Sciences Q4 EPS $(0.36) Misses $(0.32) Estimate
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.32) by 12.5 percent. This is a 38.46 percent decrease over losses of $(0.26) per share
2025-03-11 19:36
Earnings Scheduled For March 11, 2025
Companies Reporting Before The Bell • Exagen (NASDAQ:XGN) is projected to repor...
2025-03-11 16:32
Achieve Life Sciences Co-Founder to Reassume CEO Role
05:25 PM EDT, 08/26/2024 (MT Newswires) -- Achieve Life Sciences (ACHV) said late Monday that Richard Stewart, its co-founder and executive chairman, will reassume the role of its chief executive officer. John Bencich, the company's CEO for the past four years, will serve as an advisor during the tr...
2024-08-27 05:25
Oppenheimer Reiterates Outperform on Achieve Life Sciences, Maintains $11 Price Target
Oppenheimer analyst Francois Brisebois reiterates Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and maintains $11 price target.
2024-08-15 21:51
